Calamos Advisors LLC Acquires 24,147 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Calamos Advisors LLC raised its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 27.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 110,671 shares of the medical device company’s stock after purchasing an additional 24,147 shares during the period. Calamos Advisors LLC’s holdings in AtriCure were worth $3,382,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Assenagon Asset Management S.A. grew its stake in shares of AtriCure by 151.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company’s stock worth $6,425,000 after buying an additional 138,046 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of AtriCure by 31.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after acquiring an additional 119,929 shares during the last quarter. Champlain Investment Partners LLC increased its holdings in shares of AtriCure by 4.3% during the third quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock valued at $78,253,000 after acquiring an additional 115,813 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of AtriCure by 14.6% during the third quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock valued at $18,621,000 after acquiring an additional 84,700 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of AtriCure in the 3rd quarter worth about $1,991,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Stock Up 2.4 %

ATRC stock opened at $40.65 on Wednesday. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -48.98 and a beta of 1.46. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The business’s 50-day moving average is $34.89 and its two-hundred day moving average is $30.47. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11.

Analyst Ratings Changes

ATRC has been the subject of a number of analyst reports. Oppenheimer raised their price objective on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $40.00 price objective on shares of AtriCure in a report on Tuesday, December 17th. UBS Group lifted their target price on AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Canaccord Genuity Group upped their price target on AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Needham & Company LLC boosted their target price on AtriCure from $40.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.38.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.